Carnosic-Acid

Carnosic acid is the principal lipophilic phenolic diterpene of rosemary (Salvia rosmarinus, formerly Rosmarinus officinalis) and common sage (Salvia officinalis), constituting approximately 1.5 to 5 percent of dried leaf mass and serving as the primary bioactive antioxidant constituent of commercial rosemary extracts designated E392 in European food-additive regulations. The compound belongs to the abietane diterpenoid structural class and is characterized by a catechol (ortho-dihydroxybenzene) moiety on ring C of the phenanthrene skeleton that confers both direct radical-scavenging activity and, more distinctively, pro-electrophilic activation of the Keap1/Nrf2/ARE cytoprotective transcriptional pathway. Under conditions of oxidative stress, the catechol ring of carnosic acid undergoes two-electron oxidation to an ortho-quinone electrophile that forms covalent thioether adducts with reactive cysteine residues (principally Cys151, Cys273, and Cys288) on the Keap1 sensor protein, releasing the transcription factor Nrf2 from proteasomal degradation and permitting its nuclear translocation and transactivation of antioxidant response element (ARE)-driven phase 2 genes including heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC), and thioredoxin reductase 1. This pro-electrophilic mechanism is pharmacologically significant because it renders the compound conditionally active: carnosic acid is converted to its electrophilic effector form preferentially in tissues experiencing elevated reactive oxygen species flux, thereby concentrating cytoprotective gene induction at sites of pathological oxidative damage rather than systemically. The neuroprotective activity of carnosic acid has been characterized in multiple rodent models of neurodegeneration and neuroinflammation, including 6-hydroxydopamine and MPTP models of Parkinson's disease, middle cerebral artery occlusion models of ischemic stroke, controlled cortical impact models of traumatic brain injury, and transgenic mouse models of Alzheimer's disease (5xFAD). In the 5xFAD model, a diacetyl pro-drug derivative (diAcCA) with improved oral stability and approximately 20 percent greater bioavailability than the parent compound reduced amyloid plaque burden, suppressed microglial and astrocytic inflammatory gene expression, and normalized spatial and working memory at oral doses translating to feasible human-equivalent exposures. Beyond neuroprotection, carnosic acid has demonstrated preclinical anti-inflammatory activity through suppression of NF-kappaB signaling and reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in models of colitis, hepatotoxicity, periodontitis, and high-fat-diet-induced neuroinflammation; antiproliferative and pro-apoptotic activity against multiple cancer cell lines (melanoma, glioma, breast, prostate, colon, renal, esophageal) through modulation of PI3K/AKT/mTOR, MAPK, and STAT3 signaling pathways; hepatoprotective activity against acetaminophen-induced and carbon-tetrachloride-induced liver injury; and antiadipogenic activity through PPARgamma modulation. Pharmacokinetically, carnosic acid is orally bioavailable (approximately 40 to 65 percent in rodent models), undergoes extensive hepatic phase II glucuronidation, and achieves measurable plasma concentrations in humans after oral administration of standardized rosemary extract. The oral median lethal dose in mice exceeds 7100 mg/kg, and 30-day repeated-dose toxicity studies at 150 mg/kg/day in rats produced no significant histopathological changes. The Joint FAO/WHO Expert Committee on Food Additives has established an acceptable daily intake of 0 to 0.6 mg/kg body weight per day for carnosic acid and carnosol combined. Human clinical data remain limited; no registration trials have been completed for any therapeutic indication, and the compound is not approved as a medicine by any regulatory authority. This monograph reviews the chemistry, natural occurrence, and isolation of carnosic acid; the pro-electrophilic Nrf2/Keap1 mechanism in molecular detail; the pharmacokinetic record including absorption, distribution, metabolism, and elimination; the preclinical pharmacology across neuroprotective, anti-inflammatory, anticancer, and hepatoprotective domains; the limited clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions; adverse-event and safety signal; and a comparative assessment of five alternative Nrf2-activating or rosemary-derived compounds against carnosic acid on five competency standards.